Evidence map›Paper›PMID 34557403›Full record

ArticleFrontiers in oncology2021

Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma.

Irene Bagaloni, Axel Visani, Sara Biagiotti, Annamaria Ruzzo, Mohsen Navari, Maryam Etebari, Lucia Mundo, Massimo Granai, Stefano Lazzi, Alessandro Isidori and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Drug transport by red blood cells.Frontiers in physiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 6 countries.

Irene BagaloniDepartment of Biomolecular Sciences (DISB), University of Urbino, Urbino, Italy.
Axel VisaniDepartment of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy.
Sara BiagiottiDepartment of Biomolecular Sciences (DISB), University of Urbino, Urbino, Italy.
Annamaria RuzzoDepartment of Biomolecular Sciences (DISB), University of Urbino, Urbino, Italy.
Mohsen NavariDepartment of Medical Biotechnology, School of Paramedical Sciences, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
Maryam EtebariDepartment of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy.
Lucia MundoSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
Massimo GranaiSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
Stefano LazziSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
Alessandro IsidoriHematology and Transplant Center, AORMN Marche Nord, Pesaro, Italy.
Federica LoscoccoHematology and Transplant Center, AORMN Marche Nord, Pesaro, Italy.
Jiejin LiSchool of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom.
Lorenzo LeonciniSection of Pathology, Department of Medical Biotechnology, University of Siena, Siena, Italy.
Giuseppe VisaniHematology and Transplant Center, AORMN Marche Nord, Pesaro, Italy.
Mauro MagnaniDepartment of Biomolecular Sciences (DISB), University of Urbino, Urbino, Italy.
Pier Paolo PiccalugaDepartment of Experimental, Diagnostic, and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy.
University of Urbino · ITOspedali Riuniti Marche Nord · ITUniversity of Siena · ITMashhad University of Medical Sciences · IRQueen Mary University of London · GBUniversity of Bologna · ITUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Altered cellular energetic metabolism has recently emerged as important feature of neoplastic cells. Indeed, interfering with cancer cell metabolism might represent a suitable therapeutic strategy. In this study, we aimed to assess glucose metabolism activation in human lymphomas and evaluate how metformin can exert its action on lymphoma cells. We studied a large series of human lymphomas (N = 252) and an

Indexed as

anaerobic glycolysisBurkitt lymphomaglucose metabolismglycolysismetformin

Identifiers

PMID34557403
PMCPMC8454268
OpenAlexW3197664762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.